Strategic alliance between bioMérieux and COPAN
14 Januar, 2015
BioFire Defense, a bioMérieux company, receives fast-track authorization of FilmArray® Ebola Test
27 Oktober, 2014
Marcy l’Etoile (France) - October 27, 2014 - BioFire Defense, LLC of Salt Lake City, UT announced today that it has received Emergency Use Authorization by the U.S. Food and Drug Administration (FDA) for its commercial FilmArray® Ebola test (BioThreat-E test™).
bioMérieux VIRTUO™, the new generation of blood culture system, is CE-marked
23 Juli, 2014
Marcy l'Etoile, France, July 23, 2014 - bioMérieux, a world leader in the field of in vitro diagnostics, announces that VIRTUO™, the new generation of BacT/ALERT®, has been CE-marked. This uniquely innovative automated blood culture microbial detection system further enriches the offering of the BacT/ALERT® product range and is now commercially available in targeted countries that recognize CE marking. The enhanced performance of the system will help laboratories provide rapid results to clinicians to help maximize laboratory efficiency and facilitate better patient outcomes.
bioMérieux strengthens its Clostridium difficile offer with the launch of VIDAS® C. difficile GDH
26 Februar, 2014
bioMérieux, a world leader in the field of in vitro diagnostics, is pleased to announce that the launch of VIDAS® C. difficile GDH makes it the only company with the width to provide solutions for C. difficile according to different laboratory settings, patient conditions and medical needs.
BioFire Submits 510(k) Application to FDA for FilmArray® Gastrointestinal Panel
19 Februar, 2014
BioFire Diagnostics, LLC today announced that it has submitted the FilmArray Gastrointestinal (GI) Panel to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. The comprehensive FilmArray GI Panel tests for over 20 common bacteria, viruses and parasites that cause infectious diarrhea.